Australia's most trusted
source of pharma news
Monday, 09 February 2026
Posted 9 February 2026 AM
Six new medicines have joined the TGA's review list, hinting at what could arrive in Australia later this year.
The updated list of drugs under review in Australia shows Viatris filed Inpefa in October, marking roughly a year since it secured rights to the first-in-class oral, dual SGLT1/2 inhibitor for heart failure from Lexicon in all markets outside the US and Europe.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.